Literature DB >> 20056340

Positive surgical margins in soft tissue sarcoma treated with preoperative radiation: is a postoperative boost necessary?

Ali Al Yami1, Anthony M Griffin, Peter C Ferguson, Charles N Catton, Peter W M Chung, Robert S Bell, Jay S Wunder, Brian O'Sullivan.   

Abstract

PURPOSE: For patients with an extremity soft tissue sarcoma (STS) treated with preoperative radiotherapy and surgically excised with positive margins, we retrospectively reviewed whether a postoperative radiation boost reduced the risk of local recurrence (LR). METHODS AND MATERIALS: A total of 216 patients with positive margins after resection of an extremity STS treated between 1986 and 2003 were identified from our institution's prospectively collected database. Patient demographics, radiation therapy parameters including timing and dose, classification of positive margin status, reasons for not administering a postoperative boost, and oncologic outcome were collected and evaluated.
RESULTS: Of the 216 patients with a positive surgical margin, 52 patients were treated with preoperative radiation therapy alone (50 Gy), whereas 41 received preoperative radiation therapy plus a postoperative boost (80% received 16 Gy postoperatively for a total of 66 Gy). There was no difference in baseline tumor characteristics between the two groups. Six of 52 patients in the group receiving preoperative radiation alone developed a LR compared with 9 of 41 in the boost group. Five-year estimated LR-free survivals were 90.4% and 73.8%, respectively (p = 0.13).
CONCLUSIONS: We found that including the postoperative radiation boost after preoperative radiation and a margin-positive excision did not provide an advantage in preventing LR for patients treated with external beam radiotherapy. Given that higher radiation doses placed patients at greater risk for late complications such as fracture, fibrosis, edema, and joint stiffness, judicious avoidance of the postoperative boost while maintaining an equivalent rate of local control can reduce the risk of these difficult-to-treat morbidities. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20056340     DOI: 10.1016/j.ijrobp.2009.06.074

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  29 in total

1.  High-grade myxofibrosarcoma of the abdominal wall.

Authors:  Richard Antbring; Sam G Parker; Jeffrey T Lordan; Alastair Cj Windsor
Journal:  BMJ Case Rep       Date:  2017-06-02

2.  Nonrhabdomyosarcoma soft tissue sarcoma (NRSTS) in pediatric and young adult patients: Results from a prospective study using limited-margin radiotherapy.

Authors:  Christopher L Tinkle; Israel Fernandez-Pineda; April Sykes; Zhaohua Lu; Chia-Ho Hua; Michael D Neel; Armita Bahrami; Barry L Shulkin; Sue C Kaste; Alberto Pappo; Sheri L Spunt; Matthew J Krasin
Journal:  Cancer       Date:  2017-07-31       Impact factor: 6.860

Review 3.  Extremity Soft Tissue Sarcoma: Role of Local Control.

Authors:  Elyse J Brinkmann; Safia K Ahmed; Matthew T Houdek
Journal:  Curr Treat Options Oncol       Date:  2020-02-05

Review 4.  Preoperative radiotherapy for extremity soft tissue sarcoma; past, present and future perspectives on dose fractionation regimens and combined modality strategies.

Authors:  Rick L M Haas; Aisha B Miah; Cécile LePechoux; Thomas F DeLaney; Elizabeth H Baldini; Kaled Alektiar; Brian O'Sullivan
Journal:  Radiother Oncol       Date:  2015-12-21       Impact factor: 6.280

Review 5.  Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications.

Authors:  Sandro Pasquali; Alessandro Gronchi
Journal:  Ther Adv Med Oncol       Date:  2017-04-16       Impact factor: 8.168

6.  Extremity soft tissue sarcoma resections: how wide do you need to be?

Authors:  David M King; Donald A Hackbarth; Andrew Kirkpatrick
Journal:  Clin Orthop Relat Res       Date:  2012-03       Impact factor: 4.176

7.  Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study.

Authors:  Nicole J Look Hong; Francis J Hornicek; David C Harmon; Edwin Choy; Yen-Lin Chen; Sam S Yoon; G Petur Nielsen; Jackie Szymonifka; Beow Y Yeap; Thomas F DeLaney; John T Mullen
Journal:  Eur J Cancer       Date:  2012-10-22       Impact factor: 9.162

8.  Adjuvant therapy for high-risk soft tissue sarcoma in the adult.

Authors:  Alessandro Gronchi; Paolo G Casali
Journal:  Curr Treat Options Oncol       Date:  2013-09

9.  Surgical margins and handling of soft-tissue sarcoma in extremities: a clinical practice guideline.

Authors:  R Kandel; N Coakley; J Werier; J Engel; M Ghert; S Verma
Journal:  Curr Oncol       Date:  2013-06       Impact factor: 3.677

10.  Neoadjuvant treatment of soft tissue sarcoma.

Authors:  Daniela Greto; Lorenzo Livi; Calogero Saieva; Pierluigi Bonomo; Icro Meattini; Mauro Loi; Lucia Di Brina; Giovanni Beltrami; Domenico Campanacci; Guido Scoccianti; Rodolfo Capanna; Monica Mangoni; Fabiola Paiar; Alessandro Franchi; Giampaolo Biti
Journal:  Radiol Med       Date:  2013-11-26       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.